Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
160 enrolled
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
21 enrolled
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Phase 2 Withdrawn
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
44 enrolled 12 charts
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Phase 2 Withdrawn
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Phase 2 Completed
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1/2 Terminated
25 enrolled
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Completed
81 enrolled 9 charts
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3 Completed
1,551 enrolled
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
Phase 2 Terminated
4 enrolled 11 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Phase 2 Completed
455 enrolled
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Completed
122 enrolled 10 charts
REGKINE
Phase NA Terminated
26 enrolled 7 charts
REGALE
Phase NA Terminated
24 enrolled 7 charts
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Completed
151 enrolled 3 charts
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
No longer available
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Phase 3 Completed
170 enrolled 7 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
24 enrolled 6 charts
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
Phase 2 Completed
31 enrolled
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Phase 3 Withdrawn
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 2 Completed
106 enrolled 6 charts
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase 1 Completed
47 enrolled
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Unknown
800 enrolled
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
2,000 enrolled
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
1,000 enrolled
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
Phase 3 Completed
2,000 enrolled
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
Phase 2 Unknown
25 enrolled
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Phase 2 Terminated
1 enrolled
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 3 Unknown
400 enrolled
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Phase 1/2 Unknown
60 enrolled
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
Phase 3 Unknown
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
750 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2 Completed
34 enrolled 16 charts
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Phase 1 Completed
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Phase 1 Completed
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
60 enrolled
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Phase 3 Completed
254 enrolled
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Withdrawn
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
280 enrolled
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
Phase 2 Completed
11 enrolled 6 charts